Final research-target dose 2.4 mg + 2.4 mg weekly Titration length ~16 weeks Trial duration 68 weeks (REDEFINE 1 / REDEFINE 2) Route Subcutaneous, once weekly Compound Delivery: 2.4 mg / 2.4 mg Maintenance Pre-blended vials simplify weekly administration to a single injection but lock the ratio at 1:1
Your own plan may still involve adjustment based on response, side effects, and how stable your routine feels from week to week
Retatrutide doses typically increase during this period, amplifying appetite suppression and metabolic effects
There are currently four approved SGLT-2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin) that have been approved by the FDA for their use in adults
Understanding these effects helps set realistic expectations and guides appropriate management strategies
He declined to have a brain MRI or PET scan for financial reasons, choosing instead to focus on treatment